Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

21472

Shown on this page

Current sort

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search

Conditions: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Nipocalimab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 16
States / cities: Centennial, Colorado • Coral Springs, Florida • Maitland, Florida + 13 more

Conditions: Urinary Bladder Neoplasms
Interventions: TAR-200, Cetrelimab; Drug · Biological
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 32 more

Conditions: Multiple Myeloma
Interventions: JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 33
States / cities: San Diego, California • San Francisco, California • New Haven, Connecticut + 27 more

Conditions: Hemolytic Disease of the Fetus and Newborn
Interventions: Nipocalimab, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 22
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 19 more

Conditions: Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Interventions: Giredestrant, Exemestane, Fulvestrant, Tamoxifen, Everolimus, LHRH Agonist, Dexamethasone Mouth Rinse; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 373 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 55
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more

Conditions: Atrial Fibrillation
Interventions: VARIPULSE Catheter, FARAWAVE Catheter; Device
Lead sponsor: Biosense Webster, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 20
States / cities: Jonesboro, Arkansas • Fountain Valley, California • Ventura, California + 16 more

Conditions: Atrial Fibrillation
Interventions: AFSW Guided DOAC, Continuous DOAC therapy; Device · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 22 Years to 85 Years
Enrollment: 5,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 93
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 68 more

Conditions: Prostatic Neoplasms
Interventions: JNJ-101556143; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Largo, Florida • Chicago Ridge, Illinois • Carmel, Indiana + 4 more

Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions: Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration; Biological · Drug · Procedure + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,040 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 429
States / cities: Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more

Conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions: TAK-411; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 15
States / cities: La Jolla, California • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Asthma
Interventions: JNJ-95597528, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 7
States / cities: Westminster, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more

Conditions: Brain Tumor
Interventions: ExAblate transcranial system; Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts • Seattle, Washington

Clinical trials in Boston, Massachusetts

Filter and sort this location

Institutions in Boston

Live official records

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)

A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)

A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

A Study of TAK-411 in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

A Study of JNJ-95597528 in Participants With Inadequately Controlled Moderate to Severe Asthma

MRI-Guided Focused Ultrasound Feasibility Study for Brain Tumors